The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Patients with a long-term history of type 2 diabetes mellitus (T2DM) carried Candida albicans in their dental root canals more frequently when they have a primary endodontic infection.
Multidrug-resistant Candida auris is an urgent antimicrobial resistance threat and the key method of prevention is strict adherence to infection control measures.
Approximately 1 in 10 patients with candidemia had a history of recent injection drug use based on a surveillance program in the Denver metropolitan area.
Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.
A recent microbiological surveillance study found that >10% of linens tested positive for the fungi Mucorales at 20% of the hospitals included in the study.
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
Screening of asymptomatic coccidioidomycosis within a Coccidioides-endemic area allowed for identifying and managing asymptomatic cases before patients began tumor necrosis factor-α inhibitor therapy.
